王金华

王金华，博士，研究员，博士生导师，课题组长。中国医学科学院药物研究所引进人才（2015）。现任中国医学科学院药物研究所国家新药筛选中心实聘课题组长，中国医学科学院药物研究所、北京协和医学院 “协和”，中国医学科学院医学与健康科技创新工程协同创新团队首席科学家。
教育背景：
1999.8 ～ 2004.6 硕、博连读，博士，北京大学医学部
1991.8 ～ 1996.6 学士，首都医科大学
研究经历：
2015.3至今 中国医学科学院药物研究所、北京协和医学院研究员、博士生导师
2013.2 ～ 2015.3 Assistant professor, faculty. John Wayne Cancer Institute, Los Angeles, CA90404 (美国)
2010.8 ～ 2013.1 Medical scientist, John Wayne Cancer Institute, Los Angeles, CA 90404. (美国)
2007.10 ～ 2010.7 Research Associate, Department of Molecular Oncology, John Wayne Cancer Institute. Los Angeles, CA 90404. (美国)
2006.7 ～ 2007.10 Research Associate, Department of Neuropathology, Case Western Reserve University, Cleveland, Ohio USA. (美国)
2004.6 ～ 2006.6 博士后，中国医学科学院药物研究所
1996.8 ～ 1999.8 江西省人民医院
联系方式：
邮箱：wjh@imm.ac.cn
研究方向：
主要从事肿瘤的机制研究和抗肿瘤相关药物靶点的确认、药物筛选模型的建立及药物筛选、以及活性化合物的深入评价工作、利用生物信息学和网络药理学研发新药。
承担科研项目：
1. 2005 Thirty-Seventh Postdoctoral fund(NO.)
2. 2014 Award from Associates for Breast and Prostate Cancer Research
3. 2014 Award from Margie and Robert E.Peterson breast cancer program
4. 中国医学科学院药物所引进人才科研基金
5. 国家自然科学基金 (**)
6. 北京市自然科学基金（**）
7. “重大新药创制”国家科技重大专项项目，2013ZX**、现代中药创新集群与数字制药技术平台、2013/01-2016/12
8. 中国医学科学院医学与健康科技创新工程
9. “协和”研究基金
10. 活性与功能国家重点实验室”研究基金
11. “十三五”重大新药创制
论文发表，学术期刊编委及审稿人：
目前发表科研论文50余篇，其中在Journal of Clinical Investigation (JCI)， Journal of the National Cancer Institute (JNCI)， Journal of Clinical Oncology (JCO)， PNAS， Cancer research， Oncogene，Human Molecular Genetics， Journal of Investigative Dermatology ，Oncotarget，Molecular Cancer research，Breast Cancer Research Treatment， Annual of surgical oncology， Cell Biochemistry and Biophysics， Clinical Hemorheology and Microcirculation等著名期刊发表SCI论文40余篇文章。 现为ActaPharmaceuticaSinica B， Oncotarget， Pharmaceutical Biology， Molecular medicine report， Journal of Breast Cancer， Cancer Investigation， Asian Life Science，Oncology letter，中国药理学通报，药学学报，中国药学杂志等杂志编委和审稿人。

发表论文：
1. Jinhua Wang*, Ying Qu*, Partha S. Ray et al. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. Journal of Clinical Investigation. 2011;121(1):212-225. (The article was elected as highlighted article) (IF: 14.689)
2. Jinhua Wang, Wan Li, Ying Zhao et al. Members of FOX family could be drug targets of cancers. Pharmacol Ther. 2017 Aug 19. pii: S0163-7258(17)30213-9. (IF: 11)
3. Iida Y, Ciechanover A, Jinhua Wang, Dave Hoon et al. Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma. Clin Cancer Res. 2017 Aug 15; 23(16):4831-4842. (IF: 9.619)
4. Jinhua Wang*, Partha S. Ray*, Ying Qu* et al. FOXC1 is a prognostic biomarker and is functionally necessary for maintenance of aggressive cellular features in basal-like breast cancer. Cancer Research. 2010; 70(10):1-7. (The pictures in the article were chosen as the cover of magazine) (IF: 8.576)
5. Jinhua Wang, I Kuiatse, AJ Casa, AV Lee, X Cui. JNK, essential for anticancer therapy-induced apoptosis promotes cancer breast progession. Cancer Research. 2009; 69( suppl.):(2).January 15,2009 (IF：8.576)
6. Jinhua Wang, Ying Qu, Xiaojiang Cui et al. FOXC1 orchestrates basal-like breast cancer cell functions by regulating NF-KB signaling (Oncogene, 2012 Nov 8;31(45):4798-802) (IF: 7.18)
7. Jinhua Wang, Sharon Hunag, Ling Takeshima et al. Acquire resistance to braf-inhibitor by increasing EGFR expression. Journal of Investigative Dermatology. 2015; 135:532-541. (IF: 7.216)
8. Jinhua Wang, Wei hua, Sharon Huang et al. RASSF8 Regulates Progression of Cutaneous Melanoma through Nuclear Factor-κb. (Oncotarget, 2015:6:30165-30177) (IF: 6.63)
9. Jinhua Wang, Hirose H, Du G et al. P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway. Cancer Lett. 2017 Oct 28;407:66-75. (IF: 6.375)
10. Jinhua Wang, Kelly K. Chong, Yoshitaka Nakamura et al. B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma. Journal of Investigative Dermatology. 2013; 133(8):2050-8. (IF: 6.19)
11. Wen Sun, Jinhua Wang, Ciuping Chen et al. Cytosolic calcium mediates RIP1/RIP3 complex-dependent necroptosis through JNK activation and mitochondrial ROS production in human colon cancer cells. Free Radic Biol Med. 2017 Jul; 108:433-444. (IF: 5.606)
12. Jie Yu, Jinhua Wang* et al. Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. Oncotarget. 2017 Mar 28; 8(13):20751-20765. (IF: 5.168)
13. Jinhua Wang et al. Research progress on the Forkhead Box C1. Oncotarget, Accepted. (IF: 5.168)
14. Jinhua Wang, Isere Kuiatse, Adrian V. Lee et al. Sustained JNK Activity Promotes Epithelial-Mesenchymal Transition, Invasion, and Survival of Breast Cancer Cells by Regulating ERK Activation. (Molecular Cancer Research, 2010; 8(2):266-277). (The article was elected as highlighted article) (IF: 4.937)
15. Jinhua Wang*, Ying Qu*, Bingya Liu, Armando Giuliano et al. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells. (Breast Cancer Research Treatment, 2010; 121(2):311-21. (IF: 4.467)
16. Jinhua Wang, WeiboKa, DaGong Sun et al. Synergistic effect of cytokines EPO, IL-3 and SCF on the proliferation, differentiation and apoptosis of erythroid progenitor cells. Clinical Hemorheology and microcirculation. 2007; 37(4):291-9. (IF: 3.398)
17. Jinhua Wang, WeiboKa, Zhiyu Tang et al. Rheological studies on precursor cells at different stage in mice. Clinical Hemorheology and microcirculation. 2003, 29:63-69. (IF：3.398)
18. Jinhua Wang*, Xu Y, Li L et al. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer. Cancer Med. 2017 Jan; 6(1):275-287. (IF: 3.362)
19. Yang S, Wang J, Duanhua Du, et al. The natural product bergenin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting NF-kappaB activition. J. Ethnopharmacol. 2017 Mar 22; 200:147-155. (IF: 2.981)
20. Jinhua Wang, WeiboKa, DaGongSun et al. Biochemical and biophysical studies on the precursor cells of mouse erythrocytes at different stages. Cell Biochemistry and Biophysics. 2006, 45:147-156. (The article was elected as highlighted article) (IF: 2.7)
21. Jin-Hua Wang*,Qing-Shan Liu*, Jian Cui, Zhi-Hong Yang et al. A novel acute anemia model for pharmacological research in mice by compelled acute exercise. Acta Pharmacologica Sinica. (2009) 30:1643-1647. (IF: 2.521)
22. Lin Wang, Jinhua Wang*, Guanhua Du et al. Actinomycin D synergistically enhances the cytotoxicity of CDDP on KB cells by activating P53 via decreasing P53-MDM2 complex. J Asian Nat Prod Res. 2017 Jun; 19(6):630-643. (IF: 1.071)
23. Wei CJ, Jinhua Wang*, Guanhua Du et al. Synthesis and antitumor activities of sinomenine derivatives on rings A and C. J Asian Nat Prod Res. 2017 Nov 1:1-15. (IF: 1.071)
24. Jinhua Wang, WeiboKa, Dagong Sun et al Biophysical and biorheology studies on the precursor cells at different stages. Science in China (Series. C). 2002, 45: 421-428. (IF: 1.2)
25. P.S Ray, Jinhua Wang, Ying Qu, et al. Role of FOXC1 in regulation of basal-like/triple-negative breast cancer. Journal of Clinical Oncology. 2009; 27: 562S (No 15S, Part I of II). (IF: 17.255)
26. Jensen TW, Ray T, Wang Jinhua, Li X et al. Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay. J Natl Cancer Inst. 2015 Jun 3;107(8). (IF：13.584)
27. Min Feng, Yi Bao, Zhimei Li, Jinhua Wang, Dave S.B. Hoon et al. RASAL2 activates RAC1 to promote triple-negative breast cancer progression. J Clin Invest. 2014; 124(12):5291-5304. (IF: 13.261)
28. ShuetTheng Lee, min feng, Jinhua Wang et al. Protein Tyrosine Phosphatase UBASH3B is Overexpressed in Triple-Negative Breast Cancer and Promotes Invasion and Metastasis. ProcNatlAcadSci U S A. 2013, Jul 2; 110(27):11121-6. (IF: 9.598)
29. Marzese DM, Scolyer RA, Jinhua Wang, Kawas NP et al.. Epigenome-wide DNA Methylation Landscape of Melanoma Progression to Brain Metastasis Reveals Aberrations on Homeobox D Cluster Associated with Prognosis. Human Molecular Genetics, 2013; 23(1): 226-38. (IF: 7.541)
30. KatsuyaOhta, Hiromitsu Hoshino, Jinhua Wang et al. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 2015:6(5):3211-24. (IF: 6.63)
31. Sanjay P. Bagaria*, Partha S. Ray*, Jinhua Wang, Alice Chung et al. Prognostic value of basal phenotype in HER2-overexpressing breast cancer. (Annual of surgical oncology, 2012; 19(3): 935-40. (IF: 4.308)
32. Partha S Ray*, Sanjay P Bagaria*, Jinhua Wang, Jaime M Shamonki. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study. (Annual of surgical oncology, 2011 18:3839–3847 (IF: 4.308)
33. Dagong Sun, Jinhua Wang, Weijuan Yao et al. Tumorigenesis of murine erythroleukeiacell line transfected with exogenous p53 gene. Clinical Hemorheology and microcirculation. 2004, 30:117-126. (IF: 3.398)
34. Fangyun Sun* ,Xiuping Chen*, Jinhua Wang, et al. Arjunic acid, a strong free radical scavenger from Terminaliaarjuna. Am J Chin Med. 2008; 36(1):197-207291-9 (IF: 1.969)
35. Chen X, Sun F, Ma L, Jinhua Wang, Qin H, Guanhua Du. In vitro evaluation on the antioxidant capacity of triethylchebulate, an aglycone from Terminaliachebula Retz fruit. Indian Pharmacol. 2011 May; 43(3):320-3. 291-9 (IF: 0.667)
36. Marzese DM, Liu M, Huynh JL, Wang J, Morton DL, Barkhoudarian G, Kelly DF, Hoon DS. Brain metastasis is predetermined in early stage of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res. 2015 Jan; 28(1):82-93 (IF：4.619)
37. Wang Jinhua, Li Li, Liu Shiwei, Zhao Ying, Wang Lin, Du Guanhua. FOXC1 promotes melanoma by activating MST1R/PI3K/AKT pathway. Oncotarget. 2016 Dec 20; 7(51):84375-84387. (IF: 5.168)
38. Yi J, Gao R, Chen Y, Yang Z, Han P, Zhang H, Dou Y, Liu W, Wang W, Du G, Xu Y, Wang J*. Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. Oncotarget. 2017 Mar 28;8(13):20751-20765. (IF: 5.168)
39. 两种晶型尼莫地平片剂在恒河猴体内药代动力学研究. 周启蒙,王金华,杜冠华. 药学学报，2017，52(12)：1918-1923.
40.Vaspin 和肥胖及 2 型糖尿病.刘师伟,王金华,杨静.中华内分泌代谢杂志2011(27).No.5.
41.生长发育过程中血细胞流变学特性的研究进展( 综述 ).王金华,蒋玉辉,唐志宇,曾柱.中国生物医学工程学报2006(25).No.2.
42.基于FP法的EPOR 配体高通量筛选模型.王金华,韩光亮,张天泰,杜冠华.中国药理学通报2006 Jan；22（1）：114~7.
43.诃子的药理作用研究进展.王金华,孙芳云,杜冠华.中国民族医药杂志1006-6810(2006)06-0045-03
44.促红细胞生成素的信号传导及其生物学作用的研究进展.王金华,杜冠华.医学分子生物学杂质2005，2（6）：440-443.
45.用激光衍射法测量网织红细胞膜剪切弹性膜量(E)及表面粘度(μm).王金华,喀蔚波,孙大公等.中国生物医学工程学报 2005年24卷04期 468-471.
46.不同发育阶段红系造血细胞的流变特性的研究.王金华,喀蔚波,孙大公等.中国生物医学工程学报 2004(23).No.1.
47.小鼠网织红细胞微观流变学特性的研究.王金华,喀蔚波,唐志宇等.生物物理学报2004年第3期 173-177.
48.CFU及其分化细胞的生物物理特性.王金华,岳黎,唐军民等.生物物理学报 2003（19）367-371.
49.红细胞和内皮细胞的粘附研究进展.王金华,姚伟娟,喀蔚波.北京生物医学工程 2001（20）302-305.
50.病理条件下白细胞与内皮细胞的粘附.王金华,喀蔚波孙大公文宗曜.中国血液流变学杂质2000；10(4).
51.大花红景天的抗氧化性溶血作用研究.孙芳云,王金华,张斌,梁智,秦海林,杜冠华.中药药理与临床2006；22（3、4）.
52.新型CKLF1对家兔红系造血祖细胞增殖分化的影响.岳黎敏,唐军民,苏安英,唐岩,王金华,汪涛,文宗曜.解剖学报2004（35）04-382.
国际专利：
Patent 1: METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PRIMARY AND METASTATIC BASAL-LIKE BREAST CANCER AND OTHER CANCER TYPES （Patent No. US ** B2 授权日： 2015.7.7）.
Patent 2: DIAGNOSIS OF PRIMARY AND METASTATIC BASAL-LIKE BREAST CANCER AND OTHER CANCER TYPES （Patent No. EP ** B1 授权日： 2015.6.17）.
参编专著：
1. Pharmology of Danshan. ISBN:978-7-117-09935-6/R.9936. 2008, Page: 242-248
2. Animal models for human common diseases. ISBN: 978-7-81116-231-8. 2007, Page: 88-85